

Corneal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/CE5252656DCAEN.html>

Date: August 2022

Pages: 74

Price: US\$ 2,000.00 (Single User License)

ID: CE5252656DCAEN

Abstracts

Corneal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Corneal Neovascularization - Drugs In Development, 2022, provides an overview of the Corneal Neovascularization (Ophthalmology) pipeline landscape.

Corneal neovascularization is a corneal condition where oxygen deprivation and stress cause abnormal blood vessels to grow in the normally clear, translucent cornea. Predisposing factors include infections, trauma to the eye, chemical burns, immune system diseases and certain other eye conditions, such as uveitis and glaucoma. Symptoms include irritation in the eyes, dryness and pink eye or conjunctivitis and light sensitivity.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Corneal Neovascularization - Drugs In Development, 2022, provides comprehensive information on the therapeutics under development for Corneal Neovascularization (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Corneal Neovascularization (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Corneal Neovascularization and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase I and Preclinical stages are 1, 2 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Corneal Neovascularization (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Corneal Neovascularization (Ophthalmology).

The pipeline guide reviews pipeline therapeutics for Corneal Neovascularization (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Corneal

Neovascularization (Ophthalmology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Corneal Neovascularization (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Corneal Neovascularization (Ophthalmology)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Corneal Neovascularization (Ophthalmology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Corneal Neovascularization (Ophthalmology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Corneal Neovascularization - Overview

Corneal Neovascularization - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Corneal Neovascularization - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Corneal Neovascularization - Companies Involved in Therapeutics Development

Chengdu Kanghong Pharmaceuticals Group Co Ltd

FortuneRock (China) Ltd

Gene Signal International SA

Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd

Kiora Pharmaceuticals Inc

Singh Biotechnology LLC

Wntgen LLC

Corneal Neovascularization - Drug Profiles

aganirsen - Drug Profile

Product Description

Mechanism Of Action

History of Events

Antisense Oligonucleotides to target VEGFR1 for Ophthalmology and Oncology - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy for Corneal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Activate Raver-2 Protein for Ophthalmology Disorders - Drug Profile

Product Description

Mechanism Of Action

Gene Therapy to Inhibit VEGF-A for Corneal Neovascularization - Drug Profile

Product Description

Mechanism Of Action

JDE-006 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KDR-22 - Drug Profile

Product Description

Mechanism Of Action

History of Events

KH-906 - Drug Profile

Product Description

Mechanism Of Action

History of Events

Recombinant Proteins for Oncology and Ophthalmology - Drug Profile

Product Description

Mechanism Of Action

SBT-200 - Drug Profile

Product Description

Mechanism Of Action

SFR-9X0122 - Drug Profile

Product Description

Mechanism Of Action

Wnt-001 - Drug Profile

Product Description

Mechanism Of Action

Corneal Neovascularization - Dormant Projects

Corneal Neovascularization - Product Development Milestones

Featured News & Press Releases

Jan 10, 2017: Zaphyr Pharmaceuticals and gene signal enter into collaboration for GS-101 (Aganirsen) in the Middle East & North Africa region

May 12, 2014: Gene Signal announces positive data from Phase III trial of aganirsen eye drops for corneal neovascularisation due to inflammation, a rare eye disease with European Orphan Drug designation.

Jul 01, 2010: Results of a Meta-Analysis Show Neovascularization Increases Risk For Corneal Transplant Rejection And Failure

Sep 01, 2009: Gene Signal GS-101 Data Shows Safe And Effective Inhibition Of Ophthalmic Blood Vessel Growth

Aug 11, 2009: Gene Signal Announces Publication of Phase I Data Highlighting Safety of GS-101 For Diseases Of The Eye

[Appendix](#)

[Methodology](#)

[Coverage](#)

[Secondary Research](#)

[Primary Research](#)

[Expert Panel Validation](#)

[Contact Us](#)

[Disclaimer](#)

List Of Tables

LIST OF TABLES

Number of Products under Development for Corneal Neovascularization, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Corneal Neovascularization - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022

Corneal Neovascularization - Pipeline by FortuneRock (China) Ltd, 2022

Corneal Neovascularization - Pipeline by Gene Signal International SA, 2022

Corneal Neovascularization - Pipeline by Guangzhou Kangrui Biological Pharmaceutical Technologies Co Ltd, 2022

Corneal Neovascularization - Pipeline by Kiora Pharmaceuticals Inc, 2022

Corneal Neovascularization - Pipeline by Singh Biotechnology LLC, 2022

Corneal Neovascularization - Pipeline by Wntgen LLC, 2022

Corneal Neovascularization - Dormant Projects, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Corneal Neovascularization, 2022

Number of Products under Development by Companies, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Routes of Administration, 2022

Number of Products by Stage and Routes of Administration, 2022

Number of Products by Molecule Types, 2022

Number of Products by Stage and Molecule Types, 2022

I would like to order

Product name: Corneal Neovascularization Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/CE5252656DCAEN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CE5252656DCAEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

